Congenital Athymia Patient Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-21
SponsorSumitomo Pharma Switzerland GmbH
About this trial
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.
Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).
Eligibility criteria
Qualifiers
Who are scheduled for implantation with RETHYMIC within the next 30 days, or who were treated with RETHYMIC within the previous 60 days.
Who have provided written informed consent directly, or written informed consent has been provided by the patient, the parent, or legal guardian.
Disqualifiers
Written informed consent cannot be obtained.
Trial design
Treatments tested in this trial
- Cultured Thymus Tissue
Treatment groups
75 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov